Gastroenterology
Volume 129, Issue 3 , Pages 819-826 , September 2005

Increased Risk for Demyelinating Diseases in Patients With Inflammatory Bowel Disease

  • Gauree Gupta

      Affiliations

    • Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    • ,
  • Joel M. Gelfand

      Affiliations

    • Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    • Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    • ,
  • James D. Lewis

      Affiliations

    • Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    • Department of Internal Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • Corresponding Author InformationAddress requests for reprints to: James D. Lewis, MD, MSCE, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, 720 Blockley Hall, 423 Guardian Drive, Philadelphia, Pennsylvania 19104-6021. fax: (215) 573-0813.

Received 27 January 2005 ,Accepted 26 May 2005.

References 

  1. Prahalad S , Shear ES , Thompson SD , Giannini EH , Glass DN . Increased prevalence of familial autoimmunity in simplex and multiplex families with juvenile rheumatoid arthritis . Arthritis Rheum . 2002;46:1851–1856
  2. Broadley SA , Deans J , Sawcer SJ , Clayton D , Compston DA . Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey . Brain . 2000;123:1102–1111
  3. Heinzlef O, Alamowitch S, Sazdovitch V, Chillet P, Joutel A, Tournier-Lasserve E, et al. Autoimmune diseases in families of French patients with multiple sclerosis . Acta Neurol Scand . 2000;101:36–40
  4. Karni A , Abramsky O . Association of MS with thyroid disorders . Neurology . 1999;53:883
  5. Niederwieser G, Buchinger W, Bonelli RM, Berghold A, Reisecker F, Koltringer P, et al. Prevalence of autoimmune thyroiditis and non-immune thyroid disease in multiple sclerosis . J Neurol . 2003;250:672–675
  6. Bergsteinsdottir K , Yang HT , Pettersson U , Holmdahl R . Evidence for common autoimmune disease genes controlling onset, severity, and chronicity based on experimental models for multiple sclerosis and rheumatoid arthritis . J Immunol . 2000;164:1564–1568
  7. De Keyser J . Autoimmunity in multiple sclerosis . Neurology . 1988;38:371–374
  8. Heward J , Gough SC . Genetic susceptibility to the development of autoimmune disease . Clin Sci (Colch) . 1997;93:479–491
  9. Minuk GY , Lewkonia RM . Possible familial association of multiple sclerosis and inflammatory bowel disease . N Engl J Med . 1986;314:586
  10. Sadovnick AD , Paty DW , Yannakoulias G . Concurrence of multiple sclerosis and inflammatory bowel disease . N Engl J Med . 1989;321:762–763
  11. Kimura K , Hunter SF , Thollander MS , et al.   Concurrence of inflammatory bowel disease and multiple sclerosis . Mayo Clin Proc . 2000;75:802–806
  12. Rang EH , Brooke BN , Hermon-Taylor J . Association of ulcerative colitis and multiple sclerosis . Lancet . 1982;2:555
  13. Beaugerie L, Lamy P, Ganne N, Carbonnel F, Le Quintrec Y, Cosnes J, et al. Morbid associations in Crohn’s disease. Study of a series of 832 patients . Presse Med . 1997;26:892
  14. Mohan N , Edwards ET , Cupps TR , et al.   Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides . Arthritis Rheum . 2001;44:2862
  15. Anonymous The Lenercept Multiple Sclerosis Study Group The University of British Columbia MS/MRI Analysis Group . TNF neutralization in MS (results of randomized, placebo-controlled multicenter study) . Neurology . 1999;53:457–465
  16. FDA MedWatch. Detailed view: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER)—May 2004. FDA/CDER/Office of Drug Safety 2004. Available: http://www.fda.gov/medwatch/SAFETY/2004/may04.htm#Enbrel. Accessed July 28, 2004.
  17. FDA MedWatch. Detailed view: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER)—June 2004. FDA/CDER/Office of Drug Safety 2004. Available: http://www.fda.gov/medwatch/SAFETY/2004/jun04.htm. Accessed July 28, 2004.
  18. FDA MedWatch. 2004 safety alerts for drugs, biologics, medical devices, and dietary supplements. FDA/CDER/Office of Drug Safety 2004. Available: http://www.fda.gov/medwatch/SAFETY/2004/safety04.htm#remicade. Accessed July 28, 2004.
  19. Magnano MD , Robinson WH , Genovese MC . Demyelination and inhibition of tumor necrosis factor (TNF) . Clin Exp Rheumatol . 2004;22(Suppl 35):S134–S140
  20. Lis Y , Mann RD . The VAMP Research multi-purpose database in the U.K . J Clin Epidemiol . 1995;48:431–443
  21. Anonymous . The general practice research database (information for researchers) . London, England: Office for National Statistics; 1994;
  22. Garcia Rodriguez LA , Perez-Gutthann S . Use of the UK General Practice Research Database for pharmacoepidemiology . Br J Clin Pharmacol . 1998;45:419–425
  23. Strom BL . Pharmacoepidemiology . Chichester, NY: John Wiley; 2000;
  24. Kennerfalk A , Ruigomez A , Wallander MA , Wilhelmsen L , Johansson S . Geriatric drug therapy and healthcare utilization in the United Kingdom . Ann Pharmacother . 2002;36:797–803
  25. Jick H , Jick SS , Derby LE . Validation of information recorded on general practitioner based computerised data resource in the United Kingdom . BMJ . 1991;302:766–768
  26. Jick H , Terris B , Derby L , Jick S . Further validation of the information recorded on a general practitioner based computerized data resource in the United Kingdom . Pharmacoepidemiol Drug Saf . 1992;1:347–349
  27. Lewis JD , Brensinger C , Bilker WB , Strom BL . Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease . Pharmacoepidemiol Drug Saf . 2002;11:211–218
  28. Card T , Hubbard R , Logan RF . Mortality in inflammatory bowel disease (a population-based cohort study) . Gastroenterology . 2003;125:1583–1590
  29. Marrie RA, Wolfson C, Sturkenboom MC, Gout O, Heinzlef O, Roullet E, et al. Multiple sclerosis and antecedent infections (a case-control study) . Neurology . 2000;54:2307–2310
  30. Hernan MA , Jick SS , Olek MJ , Jick H . Recombinant hepatitis B vaccine and the risk of multiple sclerosis (a prospective study) . Neurology . 2004;63:838–842
  31. Lewis JD , Aberra FN , Lichtenstein GR , Bilker WB , Brensinger C , Strom BL . Seasonal variation in flares of inflammatory bowel disease . Gastroenterology . 2004;126:665–673
  32. Lewis JD , Bilker WB , Brensinger C , Deren JJ , Vaughn DJ , Strom BL . Inflammatory bowel disease is not associated with an increased risk of lymphoma . Gastroenterology . 2001;121:1080–1087
  33. Lewis J , Brensinger C , Bilker W , Strom B . Reliability of the General Practice Research Database to identify major medical events in chronic diseases (abstr) . Pharmacoepidemiol Drug Saf . 2000;10(Suppl 1):S46
  34. Pimentel M, Chang M, Chow EJ, Tabibzadeh S, Kirit-Kiriak V, Targan SR, et al. Identification of a prodromal period in Crohn’s disease but not ulcerative colitis . Am J Gastroenterol . 2000;95:3458–3462
  35. Wolfson C , Wolfson DB . The latent period of multiple sclerosis (a critical review) . Epidemiology . 1993;4:464–470
  36. Lewis JD , Bilker WB , Weinstein RL , Strom BL . Measuring incidence rates using GPRD (How soon after registration do incidence rates reach baseline levels?) . Pharmacoepidemiol Drug Saf . 2004;13:S230
  37. Lewis JD , Brensinger C . Agreement between GPRD smoking data (a survey of general practitioners and a population-based survey) . Pharmacoepidemiol Drug Saf . 2004;13:437–441
  38. Mickey RM , Greenland S . The impact of confounder selection criteria on effect estimation . [published erratum appears in Am J Epidemiol 1989;130:1066] Am J Epidemiol . 1989;129:125–137
  39. Fox CM , Bensa S , Bray I , Zajicek JP . The epidemiology of multiple sclerosis in Devon (a comparison of the new and old classification criteria) . J Neurol Neurosurg Psychiatry . 2004;75:56–60
  40. Robertson N , Compston A . Surveying multiple sclerosis in the United Kingdom . J Neurol Neurosurg Psychiatry . 1995;58:2–6
  41. MacDonald BK , Cockerell OC , Sander JWAS , Shorvon SD . The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK . Brain . 2000;123:665–676
  42. Ford HL , Gerry E , Johnson M , Williams R . A prospective study of the incidence, prevalence and mortality of multiple sclerosis in Leeds . J Neurol . 2002;249:260–265
  43. Forbes RB , Swingler RJ . Multiple sclerosis prevalence in the UK estimated by capture-recapture methodology . Am J Epidemiol . 1999;149:1016–1024
  44. Swingler RJ , Compston D . The distribution of multiple sclerosis in the United Kingdom . J Neurol Neurosurg Psychiatry . 1986;49:1115–1124
  45. Ford HL , Gerry E , Airey CM , Vail A , Johnson MH , Williams DRR . The prevalence of multiple sclerosis in the Leeds Health Authority . J Neurol Neurosurg Psychiatry . 1998;64:605–610
  46. Robertson N , Deans J , Fraser M , Compston DA . Multiple sclerosis in south Cambridgeshire (incidence and prevalence based on a district register) . J Epidemiol Community Health . 1996;50:274–279
  47. MacDonald BK , Cockerell OC , Sander JWAS , Shorvon SD . The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK . Brain . 2000;123:665–676
  48. Jones P. MS prevalence data for selected countries. All about multiple sclerosis. 1999. Multiple Sclerosis Information Trust. Accessed: January 15, 2005. Available: http://www.mult-sclerosis.org/prev_tab.html.
  49. Mayr WT , Pittock SJ , McClelland RL , Jorgensen NW , Noseworthy JH , Rodriguez M . Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985–2000 . Neurology . 2003;61:1373–1377
  50. Edwards LJ , Constantinescu CS . A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic . Mult Scler . 2004;10:575–581
  51. Thomas CW , Weinshenker BG , Sandborn WJ . Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn’s disease . Inflamm Bowel Dis . 2004;10:28–31
  52. Constantinescu CS , Whiteley AM , Blumhardt LD . Long term azathioprine fails to suppress onset of multiple sclerosis . Mult Scler . 2000;6:362–363
  53. Rizvi SA , Agius MA . Current approved options for treating patients with multiple sclerosis . Neurology . 2004;63(Suppl 6):S8–S14

 Supported by grant 5-T35-DK060441-03. J.M.G. has received research support and consulting honorarium from Amgen. J.D.L. has received consulting honorarium and research support from Wyeth during the past 2 years for work unrelated to anti–tumor necrosis factor α therapies and is a co-investigator of research funded by Johnson and Johnson but does not receive any direct compensation as part of the research.

PII: S0016-5085(05)01124-8

doi: 10.1053/j.gastro.2005.06.022

Gastroenterology
Volume 129, Issue 3 , Pages 819-826 , September 2005

Article Tools